Processa Pharmaceuticals (PCSA) Stock Price, News & Analysis

Company Overview

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

Key Stats

• Today's Range: $0.24 to $0.29
• 50-Day Range: $0.22 to $0.51
• 52-Week Range: $0.15 to $3.10
• Volume: 1.95 million shs
• Average Volume: 997,156 shs
• Market Capitalization: $1.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Buy

Processa Pharmaceuticals Stock Analysis - MarketRank™

Processa Pharmaceuticals scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Processa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Processa Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Processa Pharmaceuticals are expected to grow in the coming year, from ($4.05) to ($2.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Processa Pharmaceuticals is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Processa Pharmaceuticals is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Processa Pharmaceuticals has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

43.41% of the float of Processa Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Processa Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Processa Pharmaceuticals has recently increased by 2,108.79%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Processa Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Processa Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

43.41% of the float of Processa Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Processa Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Processa Pharmaceuticals has recently increased by 2,108.79%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Processa Pharmaceuticals this week, compared to 0 articles on an average week.

Search Interest

5 people have searched for PCSA on MarketBeat in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Processa Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.00% of the stock of Processa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

91.93% of the stock of Processa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PCSA Stock Analysis - Frequently Asked Questions

How have PCSA shares performed this year?

Processa Pharmaceuticals' stock was trading at $0.8838 at the beginning of 2025. Since then, PCSA shares have decreased by 69.3% and is now trading at $0.2710.
View the best growth stocks for 2025 here.

How were Processa Pharmaceuticals' earnings last quarter?

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) announced its earnings results on Thursday, March, 20th. The company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.18.

When did Processa Pharmaceuticals' stock split?

Processa Pharmaceuticals's stock reverse split on the morning of Monday, January 22nd 2024. The 1-20 reverse split was announced on Monday, January 22nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Processa Pharmaceuticals?

Shares of PCSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Processa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Processa Pharmaceuticals investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Jabil (JBL) and Builders FirstSource (BLDR).

Company Calendar

• Last Earnings: 3/20/2025
• Today: 5/08/2025
• Next Earnings (Estimated): 5/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PCSA
• CIK: 1533743
• Web: www.processapharmaceuticals.com
• Phone: (443) 776-3133
• Fax: 443-288-4420
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.00
• High Stock Price Target: $6.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +2,114.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-11,120,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -195.21%
• Return on Assets: -163.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.97
• Quick Ratio: 3.97

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.05 per share
• Price / Book: 0.07

Miscellaneous

• Outstanding Shares: 5,269,000
• Free Float: 2,842,000
• Market Cap: $1.43 million
• Optionable: Not Optionable
• Beta: 1.36